HODGKIN LYMPHOMA
Clinical trials for HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with lymphoma: drug combo may replace harsh chemo
Disease control Not yet recruitingThis study tests a combination of two drugs, camrelizumab and ivarmacitinib, as a first treatment for children aged 6-18 with newly diagnosed classical Hodgkin lymphoma. The goal is to see if this approach can achieve a complete metabolic response (no signs of active cancer) whil…
Matched conditions: HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Engineered immune cells take on aggressive lymphomas in new trial
Disease control Not yet recruitingThis study tests a new treatment called CD70.CAR NK cells for people with diffuse large B-cell lymphoma or Hodgkin lymphoma that did not respond to or came back quickly after initial therapy. The treatment uses specially designed immune cells from a donor to find and attack cance…
Matched conditions: HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Promising new combo aims to tame hodgkin lymphoma in young patients
Disease control Not yet recruitingThis study tests whether adding nivolumab to standard chemotherapy (AVD) can better control early-stage Hodgkin lymphoma in patients aged 2 to 21. The treatment is given to 15 participants to see if it is safe and effective. The goal is to improve outcomes while reducing long-ter…
Matched conditions: HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Can a smaller dose of this cancer drug still work? new trial aims to find out
Disease control Not yet recruitingThis phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…
Matched conditions: HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New vaccine aims to fight Hard-to-Treat EBV cancers
Disease control Not yet recruitingThis study tests a vaccine called KSD-101 in 80 people with blood cancers linked to the Epstein-Barr virus (EBV). The vaccine uses a patient's own immune cells to target EBV and cancer. Researchers want to see if it can shrink tumors or keep the disease from coming back.
Matched conditions: HODGKIN LYMPHOMA
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Can less radiation be just as good for hodgkin lymphoma?
Disease control Not yet recruitingThis phase 3 trial is testing whether a lower dose of radiation (20 Gy) is as effective as the standard dose (30 Gy) for people with early-stage, unfavorable Hodgkin lymphoma. Only patients whose cancer shows a complete metabolic response after two cycles of chemotherapy will be …
Matched conditions: HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Weekly scans may make proton therapy safer for kids with cancer
Knowledge-focused Not yet recruitingThis study will enroll 100 children with solid tumors or Hodgkin lymphoma who are receiving proton therapy. Researchers will take weekly or bi-weekly CT or MRI scans during treatment to check if the original radiation plan is still accurate. If tumor coverage drops by 5% or radia…
Matched conditions: HODGKIN LYMPHOMA
Phase: NA • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New app guides young cancer survivors through life after treatment
Knowledge-focused Not yet recruitingThis study is testing a mobile app called my.naviGATE for teens and young adults (ages 15-24) who have finished cancer treatment. The app provides personalized education, peer support, and tracks how patients are doing. Researchers want to see if the app helps patients feel more …
Matched conditions: HODGKIN LYMPHOMA
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC